Dr. Jagabandhu Das Dr. Jagabandhu Das codiscovered the dasatinib while working at Bristol Myers Squibb.
''Received Ph. D. degree in chemistry from the University of New Brunswick, Fredericton, NB, Canada in 1978. Joined Squibb Institute for Medical Research as a research investigator in 1982 after postdoctoral research in the laboratory of Prof. E. J. Corey at Harvard University. At present is a research fellow in Drug Discovery Chemistry at Bristol-Myers Squibb Pharmaceutical Research Institute. Extensive research experience in organic synthesis , and medicinal chemistry with concentration in immunology, oncology, and cardiovascular diseases. Holder of 57 issued U. S. patents and 45 publications. Listed as whos who in American Men and Women of Science, and Marquis whos who in America. Co-discoverer of the multi-kinase inhibitor dasatinib (SPRYCEL)which is currently approved for the treatment of chronic myeloid leukemia (CML), and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) in patients with resistance to or intolerant of prior therapy including imatinib.'' Extract of http://www.scientistsolutions.com/PrintTopic.aspx?id=d3ce7ca3-9617-4f2d-ab3c-e0c7b59b11d8